Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 8 of 41
Healthy Activities Improve Lives (HAIL)
NCT06267547
Permissive Hypotension After Cardiac Surgery
NCT06476613
The T1D Parent Check-In: A Preventative Intervention
NCT06160934
Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
NCT05954728
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF
NCT06099730
Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
NCT06073353
Investigation of Laser Assisted Drug Delivery of NanoDOX®
NCT05411484
Methemoglobin Concentration in High Dose Inhaled Nitric Oxide
NCT05612074
Delayed Tolerance Through Mixed Chimerism
NCT05900401
Ultrahypofractionation and Normal Tissue Toxicity
NCT05912231
Biomarker for Infection Risk in CLL and MM
NCT05844033
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
NCT05956834
Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant
NCT05709912
Niraparib In Recurrent IDH 1/2 Gliomas
NCT05406700
Virtual Health Insurance Navigation Pilot Program for Childhood Survivors (HINTII)
NCT05527392
The Boston Pace Study
NCT05869500
Psychosis TMS Study
NCT05857137
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
NCT05003648
Neuromodulation of Mind-Wandering in Depression
NCT04832685
Comparing Behavior Therapy and Yoga for Treating Depression Among Adults
NCT05546697
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
NCT05690971
Assessment of Biomarkers in Children to Help Parents Quit Tobacco
NCT04832659
Melatonin and Sleep Spindles in Autism
NCT05716906
Virtual Reality Intervention for Patients Undergoing BMT
NCT05629676
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
NCT07597239
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
NCT05040659
Circadian Influence on Prolonged Exposure Therapy for PTSD
NCT05453162
Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain
NCT05373745
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
NCT05092516
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
NCT05056896
Video Images About Decisions for Ethical Outcomes in the Emergency Department (VIDEO-ED)
NCT04931797
Niraparib in Tumors Metastatic to the CNS
NCT04992013
Anabolic Therapy in Postmenopausal Osteoporosis
NCT05010590
Pressure-enabled Delivery in Radioembolization (TriNav Study)
NCT05128032
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
NCT05034536
Lurbinectedin + Doxorubicin In Leiomyosarcoma
NCT05099666
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
NCT04902833
WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
NCT06576050
Tobramycin Injection to Prevent Infection in Open Fractures
NCT04964947
Immune and Genomic Markers in ALK+ NSCLC
NCT04881916
The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance
NCT04908358
Transcranial Photobiomodulation With Near-Infrared Light for Language in Individuals With Down Syndrome
NCT04668001
Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care
NCT05229718
The Transitions Project: Efficacy Trial
NCT05087251
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
NCT06284213
Inqovi Maintenance Therapy in Myeloid Neoplasms
NCT04980404
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
NCT04540380
Supportive Oncology Care at Home Post-Discharge
NCT04637035
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.